Feasibility of using limited-population-based average R10 for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced magnetic resonance imaging data

Magnetic Resonance Imaging

Volumn 27, Issue 6, 2009, Pages 852-858

  Huang, Wei ^a,b,c   Wang, Ya ^a   Panicek, David M ^a,b   Schwartz, Lawrence H ^a,b   Koutcher, Jason A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Dynamic contrast enhanced MRI; Ktrans; Osteosarcoma; Pharmacokinetic modeling; R1; ve

Indexed keywords

GADOLINIUM PENTETATE;

ADOLESCENT; ADULT; ANALYTICAL ERROR; ARTICLE; CHILD; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DRUG DETERMINATION; DRUG DIFFUSION; EXPERIMENTAL DESIGN; FEASIBILITY STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEG DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; POPULATION RESEARCH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOFREQUENCY; RETROSPECTIVE STUDY; SCHOOL CHILD; SIGNAL PROCESSING;

ADULT; ALGORITHMS; BONE NEOPLASMS; CHILD; COMPUTER SIMULATION; CONTRAST MEDIA; FEASIBILITY STUDIES; FEMALE; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MODELS, BIOLOGICAL; OSTEOSARCOMA; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 67049107824     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mri.2009.01.020     Document Type: Article

References (25)

1. Leach M.O., Brindle K.M., Evelhoch J.L., Griffiths J.R., Horsman M.R., Jackson A., et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92 (2005) 1599-1610
2. Knopp M.V., Weiss E., Sinn H.P., Mattern J., Junkermann H., Radeleff J., et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 10 (1999) 260-266
3. Buckley D.L., Roberts C., Parker G.J.M., Logue J.P., and Hutchinson C.E. Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging - initial experience. Radiology 233 (2004) 709-715
4. Li X., Huang W., Yankeelov T.E., Tudorica A., Rooney W.D., and Springer C.S. Shutter-speed analysis of contrast reagent bolus-tracking data: preliminary observations in benign and malignant breast disease. Magn Reson Med 53 (2005) 724-729
5. Chang E.Y., Li X., Jerosch-Herold M., Priest R.A., Enestvedt C.K., Xu J., et al. The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging. J Gastrointest Surg 11 (2007) 166-175
6. Galbraith S.M., Rustin G.J., Lodge M.A., Taylor N.J., Stirling J.J., Jameson M., et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20 (2002) 3826-3840
7. Morgan B., Thomas A.L., Drevs J., Hennig J., Buchert M., Jivan A., et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21 (2003) 3955-3964
8. Liu G., Rugo H.S., Wilding G., McShane T.M., Evelhoch J.L., Ng C., et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 23 (2005) 5464-5473
9. Mross K., Drevs J., Muller M., Medinger M., Marme D., Hennig J., et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumors. Eur J Cancer 41 (2005) 1291-1299
10. Thomas A.L., Morgan B., Horsfield M.A., Higginson A., Kay A., Lee L., et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23 (2005) 4162-4171
11. Wang Y., Huang W., Panicek D.M., Schwartz L.H., and Koutcher J.A. Feasibility of using limited-population-based arterial input function for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced MRI data. Magn Reson Med 59 (2008) 1183-1189
12. Zhou R., Pickup S., Yankeelov T.E., Springer C.S., and Glickson J.D. Simultaneous measurement of arterial input function and tumor pharmacokinetics in mice by dynamic contrast enhanced imaging: effects of transcytolemmal water exchange. Magn Reson Med 52 (2004) 248-257
13. Yankeelov T.E., Rooney W.D., Li X., and Springer C.S. Variation of the relaxographic "shutter-speed" for transcytolemmal water exchange affects the CR bolus-tracking curve shape. Magn Reson Med 50 (2003) 1151-1169
14. Dyke J.P., Panicek D.M., Healey J.H., Meyers P.A., Huvos A.G., Schwartz L.H., et al. Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology 228 (2003) 271-278
15. Parker G.J.M., Suckling J., Tanner S.F., Padhani A.R., Revell P.B., Husband J.E., et al. Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. J Magn Reson Imaging 7 (1997) 564-574
16. Parker G.J., and Tofts P.S. Pharmacokinetic analysis of neoplasms using contrast-enhanced dynamic magnetic resonance imaging. Top Magn Reson Imaging 10 (1999) 130-142
17. Li K.-L., Zhu X.P., Waterton J., and Jackson A. Improved 3D quantitative mapping of blood volume and endothelial permeability in brain tumors. J Magn Reson Imaging 12 (2000) 347-357
18. 1 values. Magn Reson Med 58 (2007) 463-472
19. Haase A. Snapshot FLASH MRI. Application to T1, T2, and chemical-shift imaging. Magn Reson Med 13 (1990) 77-89
20. Yankeelov T.E., Rooney W.D., Huang W., Dyke J.P., Li X., Tudorica A., et al. Evidence for shutter-speed variation in CR bolus-tracking studies of human pathology. NMR Biomed 18 (2005) 173-185
21. Tofts P.S. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7 (1997) 91-101
22. Li X., Rooney W.D., and Springer C.S. A unified magnetic resonance imaging pharmacokinetic theory: intravascular and extracellular contrast reagents. Magn Reson Med 54 (2005) 1351-1359
23. Tofts P.S., Berkowitz B., and Schnall M.D. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med 33 (1995) 564-568
24. Huang W., Li X., Morris E.A., Tudorica L.A., Seshan V.E., Rooney W.D., et al. The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors in vivo. Proc Natl Acad Sci 105 (2008) 17943-17948
25. Li X., Huang W., Morris E.A., Tudorica L.A., Seshan V.E., Rooney W.D., et al. Dynamic NMR effects in breast cancer dynamic-contrast-enhanced MRI. Proc Natl Acad Sci 105 (2008) 17937-17942